University System of Maryland

Affinivax, Inc.

Raphael Simon

Sharon Tennant

Myron M Levine

Alan S Cross

James Eugene Galen

Francis Michon

Richard Malley

George Rainer Siber

Teresa J Broering

Donna Ambrosino

Sharon M Tennants

Alan Cross

Technologies for the prevention and/or treatment of nosocomial infections.

Immunogenic compositions

Longer chain antigenic O-polysaccharide chains for use as a hapten in conjugate vaccines can be produced in a controlled manner using recombinant Gram-negative bacteria that overexpress native or heterologous genes of the wzz family, for example wzzB. Bacteria expressing a chosen wzz gene have modified O-polysaccharide chain lengths, allowing the bacteria to produce lipopolysaccharides having the longer O-polysaccharides. The LPS produced by the bacteria can be hydrolyzed to form core-O-polysaccharide molecules that can be conjugated to a carrier molecule, for example flagellin, to produce a vaccine. The invention also provides recombinant bacteria producing the longer chain O-polysaccharides, the polysaccharide molecules, themselves, conjugated vaccines comprising the O-polysaccharides, pharmaceutical compositions and kits.

Compositions and methods for producing bacterial conjugate vaccines

The present invention is drawn to conjugates and vaccine compositions comprising aflagellin or an antigenic fragment or derivative thereof linked to one or moresurface polysaccharide antigens, such asO polysaccharide from serovars O1, O2, O2, O3, O4, O5, O7, O8 and O12. The present invention also provides serovar reagent strains to produce the conjugates and vaccine compositions and methods of inducing an immune response with the conjugates and vaccine compositions.

Broad spectrum conjugate vaccine to prevent klebsiella pneumoniae and pseudomonas aeruginosa infections

The present invention is drawn to conjugates and vaccine compositions comprising aflagellin or an antigenic fragment or derivative thereof linked to one or moresurface polysaccharide antigens, such asO polysaccharide from serovars O1, O2a, O2a,c, O3, O4, O5, O7, O8 and 012. The present invention also provides serovar reagent strains to produce the conjugates and vaccine compositions and methods of inducing an immune response with the conjugates and vaccine compositions.

[object Object]

The present invention is drawn to attenuatedserovar strainsand, conjugate vaccines derived from these attenuated strains ofand, comprising an O polysaccharide covalently linked to a flagellin protein, and methods for inducing an immune response in a subject comprising administering the attenuated strains and/or the conjugate vaccines of the invention.

The present invention is drawn to multivalentserovar conjugate vaccines comprising conjugates ofA and optionallyB, wherein the conjugates comprise a hapten antigen and a carrier antigen, wherein at least one of the hapten antigens or carrier antigens is characteristic of theserovar. The present invention also providesserovar reagent strains to produce the multivalent conjugate vaccines and attenuatedserovars for use as vaccines.

Growing community of inventors

Baltimore, MD, United States of America

Raphael Simon